Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for DiaMedica Therapeutics, Inc. (DMAC : NSDQ)

• Company Description    DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota. Number of Employees: 35

• Price / Volume Information    Yesterday's Closing Price: $5.91 Daily Weekly Monthly 20 Day Moving Average: 167,386 shares Shares Outstanding: 53.88 (millions) Market Capitalization: $318.45 (millions) Beta: 0.99 52 Week High: $10.42 52 Week Low: $3.48 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -4.98% -9.62% 12 Week -28.19% -33.61% Year To Date -25.75% -33.36%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 301 CARLSON PARKWAY SUITE 210 - MINNEAPOLIS,MN 55305 USA ph: 763-496-5454 fax: 763-710-4456 skellen@diamedica.com http://www.diamedica.com

• General Corporate Information    Officers Rick Pauls - Chief Executive Officer; President and Director James Parsons - Chairman of the Board; Director Scott Kellen - Chief Financial Officer and Secretary Michael Giuffre - Director Tanya N. Lewis - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 25253X207 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 53.88 Most Recent Split Date: 11.00 (0.05:1) Beta: 0.99 Market Capitalization: $318.45 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.19 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.86 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.74 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -5.56% vs. Previous Quarter: -11.76% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -77.15 12/31/25 - -77.72 09/30/25 - -83.22 ROA 03/31/26 - -69.23 12/31/25 - -69.54 09/30/25 - -73.53 Current Ratio 03/31/26 - 9.11 12/31/25 - 11.81 09/30/25 - 10.67 Quick Ratio 03/31/26 - 9.11 12/31/25 - 11.81 09/30/25 - 10.67 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 0.88 12/31/25 - 1.08 09/30/25 - 0.99 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.01 09/30/25 - 0.01

Powered by Zacks Investment Research ©